Wick, W., Platten, M., & Wick, A. (2016). Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clinical cancer research, 22(19), . https://doi.org/10.1158/1078-0432.CCR-15-3153
Chicago-Zitierstil (17. Ausg.)Wick, Wolfgang, Michael Platten, und Antje Wick. "Phase II Study of Radiotherapy and Temsirolimus Versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma Without MGMT Promoter Hypermethylation (EORTC 26082)." Clinical Cancer Research 22, no. 19 (2016). https://doi.org/10.1158/1078-0432.CCR-15-3153.
MLA-Zitierstil (9. Ausg.)Wick, Wolfgang, et al. "Phase II Study of Radiotherapy and Temsirolimus Versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma Without MGMT Promoter Hypermethylation (EORTC 26082)." Clinical Cancer Research, vol. 22, no. 19, 2016, https://doi.org/10.1158/1078-0432.CCR-15-3153.